Severe, poorly controlled asthma might increasingly be managed with monthly injections
Jacob Wackerhausen/Getty Images
Individuals suffering from severe asthma often depend on daily steroid medications, raising their likelihood of diabetes, infections, and bone issues. A new study indicates that monthly antibody injections could serve as a safer alternative.
When asthma is unmanageable with an inhaler, steroid drugs are commonly used, effectively decreasing airway inflammation and alleviating symptoms alongside the risk of asthma attacks. However, these medications can lead to serious side effects. “We aim to minimize the usage of oral steroids,” says Fan Chun from Imperial College London, who was not part of the research.
Previous studies demonstrated that tezepelumab, a monthly antibody injection, reduces the symptoms of severe asthma more effectively than a placebo. This has led to its approval in several countries, including the UK and the US, over recent years. However, it remained uncertain whether this treatment could lessen or eliminate the reliance on steroid drugs.
To investigate this, David Jackson and his colleagues at Guy’s and St Thomas’ Hospital in London recruited 298 individuals aged 18 to 80 with severe asthma from 11 countries. Participants were already using daily inhalers and steroids and were asked to take tezepelumab for one year. Chung noted that a control group wasn’t necessary since prior trials established that the injection had a significant effect compared to a placebo.
Researchers observed that, under medical supervision, participants’ oral steroid doses gradually decreased throughout the study.
By the end of the year, around half of the participants no longer required steroid medication, while 40% were able to reduce their doses enough to “minimize side effects,” according to Chung. “This outcome is highly successful,” he stated. “The trial confirms that tezepelumab is an effective treatment for patients with severe asthma, decreasing the need for daily medications.”
Side effects, such as worsening asthma symptoms, were reported by 9% of participants. However, it is unclear if these were due to the injection or existed beforehand, Chong explained. Nonetheless, he considers the rate acceptable given the advantages of reducing steroid use.
topic:
Source: www.newscientist.com
